# Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan

> **NCT05248919** · NA · ENROLLING_BY_INVITATION · sponsor: **Queen Mary University of London** · enrollment: 318 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Epclusa (nucleotide HCV NS5B polymerase inhibitors).

## Key facts

- **NCT ID:** NCT05248919
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-06-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-09
- **Target enrollment:** 318 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248919, "Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05248919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*